These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study. Rog D; Brownlee W; Carod-Artal FJ; Kalra S; Barker N; Lowndes C; Pendlebury J; Leclerc S; Amin A; Ashton L; Evans H; De Cock E Mult Scler Relat Disord; 2024 Feb; 82():105380. PubMed ID: 38183696 [TBL] [Abstract][Full Text] [Related]
4. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609 [TBL] [Abstract][Full Text] [Related]
5. Novel Agents for Relapsing Forms of Multiple Sclerosis. Straus Farber R; Harel A; Lublin F Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. Chirikov V; Ma I; Joshi N; Patel D; Smith A; Giambrone C; Cornelio N; Hashemi L Value Health; 2019 Feb; 22(2):168-176. PubMed ID: 30711061 [TBL] [Abstract][Full Text] [Related]
7. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. Merkel B; Butzkueven H; Traboulsee AL; Havrdova E; Kalincik T Autoimmun Rev; 2017 Jun; 16(6):658-665. PubMed ID: 28428119 [TBL] [Abstract][Full Text] [Related]
8. The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis. Heath G; Airody A; Gale RP Drugs; 2017 Mar; 77(3):303-311. PubMed ID: 28181178 [TBL] [Abstract][Full Text] [Related]
9. [Magnetic resonance imaging of the brain in the monitoring of immune therapy of multiple sclerosis]. Elovaara I; Soilu-Hänninen M; Kuusisto H; Martola J; Tienari P; Färkkilä M; Remes AM Duodecim; 2015; 131(17):1571-80. PubMed ID: 26548104 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643 [TBL] [Abstract][Full Text] [Related]
11. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806 [TBL] [Abstract][Full Text] [Related]
12. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Fernández Ó Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479 [TBL] [Abstract][Full Text] [Related]
13. The use of immune modulating drugs for the treatment of multiple sclerosis. Al-Khamis FA Neurosciences (Riyadh); 2016 Jan; 21(1):4-9. PubMed ID: 26818160 [TBL] [Abstract][Full Text] [Related]
14. How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). Bigaut K; Cohen M; Durand-Dubief F; Maillart E; Planque E; Zephir H; Lebrun-Frenay C; de Seze J; Mult Scler Relat Disord; 2021 Aug; 53():103076. PubMed ID: 34161898 [TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. Piena MA; Heisen M; Wormhoudt LW; Wingerden JV; Frequin STFM; Uitdehaag BMJ J Med Econ; 2018 Oct; 21(10):968-976. PubMed ID: 29911917 [TBL] [Abstract][Full Text] [Related]
17. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab. Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625 [TBL] [Abstract][Full Text] [Related]
18. PML: The Dark Side of Immunotherapy in Multiple Sclerosis. Warnke C; Olsson T; Hartung HP Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099 [TBL] [Abstract][Full Text] [Related]